B
13.40
0.00 (0.00%)
Penutupan Terdahulu | 13.40 |
Buka | 13.39 |
Jumlah Dagangan | 308,591 |
Purata Dagangan (3B) | 443,245 |
Modal Pasaran | 729,169,024 |
Harga / Buku (P/B) | 1.41 |
Julat 52 Minggu | |
Tarikh Pendapatan | 27 Mar 2025 |
EPS Cair (TTM) | -1.09 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 0.09% |
Nisbah Semasa (MRQ) | 36.01 |
Aliran Tunai Operasi (OCF TTM) | -52.76 M |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Bercampur |
Biotechnology (Global) | Bercampur | Bercampur | |
Stok | Bicara Therapeutics Inc. | Menurun | - |
AISkor Stockmoo
0.0
Konsensus Penganalisis | 1.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 0.5 |
Purata | 0.00 |
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. |
|
Sektor | Healthcare |
Industri | Biotechnology |
% Dimiliki oleh Orang Dalam | 6.26% |
% Dimiliki oleh Institusi | 86.04% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Red Tree Management, Llc | 31 Dec 2024 | 3,170,509 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 45.00 (HC Wainwright & Co., 235.82%) | Beli |
Median | 31.00 (131.34%) | |
Rendah | 13.01 (Cantor Fitzgerald, -2.91%) | Beli |
Purata | 29.67 (121.42%) | |
Jumlah | 3 Beli | |
Harga Purata @ Panggilan | 12.74 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Cantor Fitzgerald | 13 Mar 2025 | 13.01 (-2.91%) | Beli | 13.35 |
Wedbush | 12 Feb 2025 | 31.00 (131.34%) | Beli | 13.22 |
06 Feb 2025 | 31.00 (131.34%) | Beli | 12.60 | |
HC Wainwright & Co. | 27 Jan 2025 | 45.00 (235.82%) | Beli | 11.65 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
27 Mar 2025 | Pengumuman | Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
25 Mar 2025 | Pengumuman | Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |